Orthocell Ltd has released a press release.
Orthocell Hits US Milestone - 100 Remplir Units Sold.
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Orthocell
- Remplir Regulatory Application for US$750m EU-UK Market
- First Commercial Sales of Remplir Achieved in Hong Kong
- Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide
- Remplir gains momentum in nerve-sparing prostate surgery
- 2nd Distributor in Canada, Entire $75m Market Now Covered
Later from Orthocell
- Orthocell Posts Seventh Straight Record Revenue Quarter
- Quarterly Activity Report & Appendix 4C
- US Market and Operational Update
- Orthocell Receives $3.0m R&D Tax Refund
- Appendix 4D & Half-Year Financial Report
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell